Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Multimodal Hypersprectal Imaging and Raman Spectroscopy for Intraoperative Assessment of Breast Tumor Resection Margins

Project description

Optical techniques to improve breast-conserving surgery

Breast-conserving surgery (a lumpectomy) is meant to remove the cancer while leaving as much of the breast as possible. Defining the tumour margin to ensure the cancer is completely removed is currently done primarily post-operatively, resulting in approximately one in five patients requiring a second surgery. Funded by the European Innovation Council, the Spectra-BREAST project aims to revolutionise breast-conserving surgery by providing a tool to assess tumour margins during surgery with over 95 % accuracy and in under five minutes. Combining hyperspectral imaging, Raman spectroscopy and AI, it will identify cancerous tissue up to two millimetres deep, improving patient outcomes, reducing healthcare costs and enabling broader applications in other cancer surgeries and biopsies.

Objective

The Spectra-BREAST project aims to revolutionize the assessment of tumor resection margins during breast conserving surgery (BCS). Currently, approximately 20% of breast cancer patients require a second operation due to incomplete removal of cancerous tissue. This results in increased costs for the healthcare system and significant negative effects on patients’ well-being.
Nowadays, the standard margin assessment procedure is postoperative histopathological specimen analysis, which takes several days to complete. Although intraoperative histopathological analysis on frozen tissue is possible, it is less effective and cannot be implemented in all clinical centers. Alternative techniques have been suggested but have low diagnostic performance or take excessive time to assess the entire resected specimen.
Spectra-BREAST aims to support surgeons with an intraoperative tool providing accurate and actionable feedback on the resection margin status over the whole specimen in less than 5 minutes. To this end, we will apply a radically new, high-risk multimodal approach combining two optical techniques, Hyperspectral Imaging (HSI) and fiber-optic Raman Spectroscopy (RS) with AI-based data-analysis. HSI and AI will be used for fast and sensitive detection of suspicious margins, which are subsequently analyzed by RS, and a second AI will make the final prediction on the RS spectra. The ambition is to identify tumors on and below the resection surface (up to a depth of 2 mm), with an unprecedented high sensitivity and specificity (over 95%) in real-time. Spectra-BREAST also has the potential for wider applications, going beyond breast cancer to include margin assessment for other cancers, robotic/laparoscopic surgery, and guided biopsy. Finally, Spectra-BREAST will offer an objective technology reducing variability between patients, and most importantly, will improve patient outcomes such as reduced hospital stays, complications, anxiety, and improved cosmetic outcomes.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-EIC - HORIZON EIC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-EIC-2024-PATHFINDEROPEN-01

See all projects funded under this call

Coordinator

ISTITUTI CLINICI SCIENTIFICI MAUGERI SOCIETA' PER AZIONI SOCIETA' BENEFIT
Net EU contribution
€ 638 293,75
Address
VIA SALVATORE MAUGERI 4
27100 Pavia
Italy
Region
Nord-Ovest Lombardia Pavia
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 638 293,75

Participants (5)